Program
daprodustat
Also written as “GSK1278863”, “Daprodustat” and “Daprodustat (GSK1278863)”.
Its studies are mostly in Anemia · Diabetic Foot · Peripheral Vascular Diseases · Tendon Injuries, led by 2 companies.
Drug pageGSK1278863: every studyAll 34 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKlineits history only | 320 open or running | phase 3since Jun 2, 2016 | Jun 16, 2011 | none ahead |
| Qilu Pharmaceuticalits history only | 11 open or running | phase 3since Dec 10, 2025 | Dec 10, 2025 | May 2027phase 3 · NCT07300111 |
Also a collaborator on its studies: Q2 Solutions, Quintiles, HemoCue and PPD DEVELOPMENT, LP.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 16 studies since Jun 16, 2011.
- Jun 9, 2015Named daprodustatINNProposed as its International Nonproprietary Name in WHO's List 113 · before, GSK1278863
- Feb 11, 2016Phase 2 study in AnemiaGlaxoSmithKline · NCT02689206 · 103 enrolled · United States, Canada, Germany and more
- Jun 2, 2016Phase 3 study in AnemiaGlaxoSmithKline · NCT02791763 · 355 enrolled · Japan
- Jul 8, 2016Phase 3 study in AnemiaGlaxoSmithKline · NCT02829320 · 28 enrolled · Japan
- Aug 19, 20162 phase 3 studies in AnemiaGlaxoSmithKline · NCT02876835, NCT02879305
- Jan 20, 2017Phase 2 study in AnemiaGlaxoSmithKline · NCT03029247 · 105 enrolled · United States
- Jan 20, 2017Phase 3 study in AnemiaGlaxoSmithKline · NCT03029208 · 312 enrolled · United States, Argentina, Australia and more
- Jul 17, 20172 phase 1 studies in AnemiaGlaxoSmithKline · NCT03239522, NCT03223337
- Jan 8, 20182 phase 3 studies in AnemiaGlaxoSmithKline · NCT03409107, NCT03400033
- Feb 20, 2018Phase 2 study in AnemiaGlaxoSmithKline · NCT03446612 · 6 enrolled · United Kingdom
- Mar 1, 2018Phase 2 study in AnemiaGlaxoSmithKline · NCT03457701 · 15 enrolled · United States
- Apr 4, 2018Phase 1 study in AnemiaGlaxoSmithKline · NCT03493386 · 64 enrolled · Japan
- Nov 18, 2020Phase 1 study in AnemiaGlaxoSmithKline · NCT04640311 · 259 enrolled · United States
- Jan 4, 2023Phase 3 study in AnemiaGlaxoSmithKline · NCT05682326 · 4 enrolled · Japan, South Korea
- Dec 10, 2025Qilu Pharmaceutical’s first study: phase 3 study in AnemiaNew to Qilu PharmaceuticalQilu Pharmaceutical · NCT07300111 · 100 planned
Ahead
- May 2027Primary completion: phase 3 study in AnemiaQilu Pharmaceutical · NCT07300111
TargetBeta
“Hypoxia-inducible factor prolyl hydroxylase inhibitor”ChEMBL 37, by rule
Other programs on the same 4 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| roxadustatrule | Astellas Pharma | phase 4 | 47 |
Studies
All 33 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07300111Anemia | 3 | Not yet recruiting | Qilu Pharmaceutical | May 2027 | 100 |
| NCT05682326Anemia · Japan, South Korea | 3 | Completed | GlaxoSmithKline | Oct 18, 2024 | 4 |
| NCT04640311Anemia · United States | 1 | Completed | GlaxoSmithKline | May 18, 2021 | 259 |
| NCT03493386Anemia · Japan | 1 | Completed | GlaxoSmithKline | Jun 9, 2018 | 64 |
| NCT03457701Anemia · United States | 2 | Completed | GlaxoSmithKline | Jul 5, 2022 | 15 |
| NCT03446612Anemia · United Kingdom | 2 | Terminated | GlaxoSmithKline | May 29, 2019 | 6 |
| NCT03409107Anemia · United States, Argentina, Australia and more | 3 | Completed | GlaxoSmithKline | Oct 7, 2020 | 614 |
| NCT03400033Anemia · United States, Argentina, Australia and more | 3 | Completed | GlaxoSmithKline | Jun 19, 2020 | 407 |
| NCT03223337Anemia · United States | 1 | Completed | GlaxoSmithKline | Aug 20, 2018 | 37 |
| NCT03239522Anemia · United Kingdom | 1 | Completed | GlaxoSmithKline | Nov 28, 2017 | 6 |
| NCT03029247Anemia · United States | 2 | Completed | GlaxoSmithKline | Jul 9, 2020 | 105 |
| NCT03029208Anemia · United States, Argentina, Australia and more | 3 | Completed | GlaxoSmithKline | Sep 24, 2020 | 312 |
| NCT02879305Anemia · United States, Argentina, Australia and more | 3 | Completed | GlaxoSmithKline | Nov 9, 2020 | 2,964 |
| NCT02876835Anemia · United States, Argentina, Australia and more | 3 | Completed | GlaxoSmithKline | Apr 19, 2021 | 3,872 |
| NCT02829320Anemia · Japan | 3 | Completed | GlaxoSmithKline | May 16, 2017 | 28 |
| NCT02791763Anemia · Japan | 3 | Completed | GlaxoSmithKline | Oct 26, 2018 | 355 |
| NCT02689206Anemia · United States, Canada, Germany and more | 2 | Completed | GlaxoSmithKline | Jan 25, 2017 | 103 |
| NCT02371603Anemia · United States | 1 | Completed | GlaxoSmithKline | Aug 12, 2015 | 70 |
| NCT02293148Anemia · United States | 1 | Completed | GlaxoSmithKline | Mar 10, 2015 | 61 |
| NCT02231190Tendon Injuries · United States | 1 | Completed | GlaxoSmithKline | Jun 12, 2015 | 26 |
| NCT02243306Anemia · United States | 1 | Completed | GlaxoSmithKline | May 10, 2017 | 8 |
| NCT02075463Anemia · United States | 2 | Terminated | GlaxoSmithKline | Mar 16, 2016 | 15 |
| NCT02019719Anemia · Japan | 2 | Completed | GlaxoSmithKline | Aug 6, 2014 | 97 |
| NCT01977573Anemia · United States, Australia, Canada and more | 2 | Completed | GlaxoSmithKline | May 1, 2015 | 252 |
| NCT01977482Anemia · United States, Australia, Canada and more | 2 | Completed | GlaxoSmithKline | Feb 1, 2015 | 216 |
| NCT01920594Surgical Procedures · United States, Canada | 2 | Completed | GlaxoSmithKline | Oct 8, 2014 | 57 |
| NCT01831804Diabetic Foot · United States | 1 | Completed | GlaxoSmithKline | Feb 10, 2017 | 65 |
| NCT01673555Anemia · United States | 1 | Completed | GlaxoSmithKline | Nov 19, 2012 | 49 |
| NCT02135848Peripheral Vascular Diseases · United States | 2 | Completed | GlaxoSmithKline | Nov 1, 2011 | 46 |
| NCT01587924Anemia · United States, Canada, Denmark and more | 2 | Completed | GlaxoSmithKline | May 27, 2013 | 80 |
| NCT01587898Anemia · United States, Canada, Germany | 2 | Completed | GlaxoSmithKline | May 7, 2013 | 72 |
| NCT01406340Anemia · United States | 1 | Terminated | GlaxoSmithKline | Aug 31, 2013 | 22 |
| NCT01376232Anemia · India | 1 | Completed | GlaxoSmithKline | Dec 20, 2010 | 23 |
How it is read
Names in the registry
- “GSK1278863”, 15 entries
- “Daprodustat”, 9 entries
- “Daprodustat (GSK1278863)”, 2 entries
- “Daprodustat tablets”, 1 entry
- “1 to 4 mg tablets of GSK1278863”, 1 entry
Codes read as this program: GSK1278863.
Conditions, from the studies’ own filings
- Anemia, 29 studies
- Diabetic Foot, 1 study
- Peripheral Vascular Diseases, 1 study
- Tendon Injuries, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.